<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04005365</url>
  </required_header>
  <id_info>
    <org_study_id>2019/prop/GC/CSU</org_study_id>
    <nct_id>NCT04005365</nct_id>
  </id_info>
  <brief_title>Clinical Study of Propranolol Combined With Neoadjuvant Chemotherapy in Gastric Cancer</brief_title>
  <official_title>Efficacy and Safety of Propranolol Combined With Neoadjuvant Chemotherapy in Stage III-IV Gastric Cancer: an Open-lable, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yijing He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      At the cellular and animal level, we found that propranolol can inhibit the proliferation and
      invasion of gastric cancer cells. Further, we want to explore the efficacy and safety of
      propranolol in the treatment of gastric cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Preoperative assessment</time_frame>
    <description>CR+PR</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Prop+neochemo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>add propranolol in gastric cancer patients who need to receive preoperate chemotherapy</description>
    <arm_group_label>Prop+neochemo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must provide written informed consent.

          2. age 18 to 75;Confirmed as a primary gastric adenocarcinoma patient by imaging and
             histology or cytology;

          3. Patients with advanced gastrointestinal cancer who have received no prior chemotherapy
             or radiotherapy for malignant tumors;

          4. Patients with Eastern Cooperative Oncology Group Performance Status of 0 or 1.

          5. Patients with a life expectancy of at least three months.;

          6. Organ function and hematopoietic function must meet the following requirements:
             hemoglobin (HGB) ≥ 90g / L; white blood cell count (WBC) ≥ 3 × 10 ^ 9 / L; absolute
             neutrophil count (ANC) ≥ 1.5 × 10 ^ 9 / L Platelet count (PLT) ≥ 100 × 10 ^ 9 / L;
             total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase
             (AST) and alanine aminotransferase ( ALT)≤2.5×ULN; if abnormal liver function is due
             to tumor liver metastasis, AST or ALT≤5×ULN; serum creatinine (Cr)≤1.5×ULN;
             international normalized ratio (INR) or plasma prothrombin time ( PT) ≤ 1.5 × ULN.

          7. Systolic blood pressure 90-140mmHg, diastolic blood pressure 60-90mmHg, heart rate
             60-100bpm.

          8. No previous cardiovascular and cerebrovascular diseases, and exclusion of
             atrioventricular block by 24-hour ambulatory electrocardiography;

          9. subjects must agree to take effective contraceptive measures between the subject and
             the partner after signing the informed consent, during the study period and within 5
             months after the last dose.

        Exclusion Criteria:

          1. There are clinical symptoms or diseases of the heart that are not well controlled,
             such as uncontrolled high blood pressure, unstable angina, or myocardial infarction
             within 6 months prior to enrollment, or poorly controlled arrhythmias (including QTc (
             men ≥ 450ms , female ≥ 470ms, QTc interval calculated by Fridericia formula),
             cardiogenic shock, heart block (II-III degree atrioventricular block), severe or acute
             heart failure, sinus bradycardia, need continuous oxygen Treated severe respiratory
             diseases;

          2. Subjects with symptomatic autoimmune diseases [such as, but not limited to,
             interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation,
             vasculitis, nephritis, hyperthyroidism, decreased thyroid function; The tester has
             vitiligo or has completely relieved asthma in childhood, and can be included without
             any intervention after adulthood; asthma that requires bronchodilators for medical
             intervention cannot be included]

          3. Patients with other malignant tumors within 5 years prior to enrollment, in addition
             to appropriate treatment of cervical carcinoma in situ, cured skin basal cell
             carcinoma;

          4. Immunodeficiency, such as a patient with HIV infection or other acquired, congenital
             immunodeficiency disease, or a history of organ transplantation

          5. Patients with active tuberculosis infection by medical history or CT examination, or a
             history of active tuberculosis infection within 1 year prior to enrollment, or
             patients with a history of active tuberculosis infection more than 1 year without
             formal treatment;

          6. Patients with tumor brain metastasis and bone marrow metastasis

          7. Patients who participated in other drug clinical studies within 4 weeks;

          8. Patients with history of hypersensitivity to any drugs in this study;

          9. Identified as neurological or psychiatric disorders, such as epilepsy, dementia, poor
             compliance;

         10. Alcohol abuse, drug abuse in the past year;

         11. Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA (HBV DNA) &gt; 10
             ^ 3 copies / mL, or hepatitis C virus antibody positive; syphilis positive;

         12. Subjects had active infection or unexplained fever &gt;38.5 degrees during Screening
             period before the first dose (according to the researcher, the subject can be enrolled
             due to fever generated by the tumor.);

         13. Clinical symptoms of ascites or pleural effusion, requiring therapeutic puncture or
             drainage;

         14. Female patients who are pregnant or lactating, or planning to become pregnant or
             lactating;

         15. Other patients who are considered to be unsuitable for this study by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yijing He, MD, PhD</last_name>
      <phone>+86-15874812612</phone>
      <email>yijinghe@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 29, 2019</study_first_submitted>
  <study_first_submitted_qc>June 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>Yijing He</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>propranolol</keyword>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

